Bio Pharma Dive
FEBRUARY 1, 2022
The collaboration with GenEdit, a South San Francisco startup developing new ways of delivering gene editing tools into the body, dates back to December 2020, but has recently begun to advance.
World of DTC Marketing
FEBRUARY 3, 2022
The way people make treatment decisions is changing because of COVID. Agencies are responsible for working with clients to implement changes that support brand objectives. It won’t be easy and means changing the mindset from a vendor to a strategic partner. If you work in an agency, your job is not to develop a website or TV spot. You need to work with pharma clients to educate them on the complicated path from awareness to requesting an Rx.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Mirror
FEBRUARY 4, 2022
Rockville, Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced its role as a Data Coordinating Center on a team whose work has accelerated pediatric COVID-19 research through the Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care (POP02).
Scienmag
FEBRUARY 3, 2022
New Jersey Institute of Technology (NJIT) has reaffirmed its status among the nation’s most elite and productive research institutions by once again achieving an R1 status — the highest designation — by the Carnegie Classification. Credit: NJIT New Jersey Institute of Technology (NJIT) has reaffirmed its status among the nation’s most elite and productive research […].
Bio Pharma Dive
FEBRUARY 4, 2022
Gene therapy developers have struggled to secure reimbursement in Europe, making Orchard's deal with the National Health Service in England and Wales a notable accomplishment.
World of DTC Marketing
FEBRUARY 2, 2022
Biogen will partner with Roche on the development, and potential sale of a promising cancer drug the Swiss pharma is advancing for several types of lymphoma, announcing Tuesday it’s exercised an option to share rights to the treatment. But is it too late for Biogen to stage a comeback with their reputation damaged? Biogen executives vowed to fight hard to reverse Medicare’s preliminary decision to sharply limit coverage of the company’s Alzheimer’s drug while saying more
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Outsourcing Pharma
FEBRUARY 3, 2022
A leader from the artificial intelligence insights specialist talks discusses how the effective use of advanced analytics can lead to a number of benefits.
Bio Pharma Dive
FEBRUARY 1, 2022
Despite the growing threat of drug-resistant bacteria, few new antibiotics are reaching the market because of hurdles that biotech executives and experts say stand in the way.
World of DTC Marketing
FEBRUARY 1, 2022
According to STAT News “after a double-digit decline in 2021, the sector has fallen another 20% in the new year, erasing billions in value and leading even the most seasoned investors to question whether biotech has further to fall. Can small biotech companies survive? Many large pharmaceutical companies reported record performances in 2021, whether that’s a decade-high stock price or shares that outperformed the broader market as investors continued to pour money into companies maki
Scienmag
FEBRUARY 4, 2022
Even the finest particles of pollution influence the process of cloud formation and the rainfall regime. A study conducted in Manaus, the capital of Amazonas state in Brazil’s North region, shows that oxidation leads small aerosols expelled by factories and car exhausts, for example, to grow very rapidly, reaching up to 400 times their original […].
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Outsourcing Pharma
FEBRUARY 1, 2022
On World Cancer Day, the Union for International Cancer Control is launching a three-year campaign with the goal to improve cancer care around the globe.
Bio Pharma Dive
JANUARY 31, 2022
The drug, which will be sold as Vabysmo, is the first of several emerging competitive threats to Regeneron's top-selling Eylea, along with biosimilars and long-acting implants.
pharmaphorum
JANUARY 31, 2022
People with long-lasting symptoms of breathlessness after COVID-19 infection may have damage to their lungs that does not show up using routine diagnostic scans, according to a small UK study. The researchers from Oxford, Sheffield, Cardiff and Manchester universities used a new form of diagnostic that involves patients breathing in the inert gas xenon whilst undergoing an MRI scan, which allows them to gauge how well gases like oxygen are being transferred from the lungs to blood vessels.
XTalks
FEBRUARY 2, 2022
Since cryptocurrencies and the Metaverse are based in the digital realm and food is firmly rooted in the physical, they might not seem like the most intuitive pairing. But back to the early days of crypto, the very first use case for Bitcoin was related to food. In the spring of 2010, two Papa John’s pizzas were purchased for 10,000 BTC, which would be worth about $389,500,000 today.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
BioPharma Reporter
JANUARY 31, 2022
Biogen releases further details on how its Phase 4 post-marketing confirmatory study for Alzheimerâs drug, Aduhelm, will run: including increased enrolment and enhanced efforts to encourage diversity.
Bio Pharma Dive
FEBRUARY 4, 2022
In a regulatory filing, Biogen said the FTC and the SEC are looking for information about Aduhelm's approval and marketing, meaning the drug is now the focus of four government probes.
pharmaphorum
FEBRUARY 1, 2022
Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials. But what does it take to implement these innovations? Can the combined potential of new AI technologies and real-world patient data hold the key to overcoming the challenges in clinical trial design that have historically led to trial failure?
Scienmag
FEBRUARY 1, 2022
A new study has revealed that the rich native tree diversity in South and Southeast Asia is at risk of potential extinction. The region-wide and spatially explicit threat assessment focused on 63 socio-economically important native trees in Asia, showing that all species are highly vulnerable to at least one of the common threats in the […].
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
BioPharma Reporter
FEBRUARY 1, 2022
US government agency, BARDA, is drawing on industry feedback to assist it in understanding the advanced developmental landscape of next-generation COVID-19 vaccines.
Bio Pharma Dive
FEBRUARY 1, 2022
William Pao led discovery and early development at the Swiss drugmaker, and will now head Pfizer's global efforts to launch new products.
NY Times
FEBRUARY 4, 2022
Tower Health Medical Group said in a statement that it learned of the allegations on Wednesday. After an investigation, the doctor’s employment was “terminated effective immediately.”.
pharmaphorum
FEBRUARY 4, 2022
The approval of Novavax’ COVID-19 vaccine in Great Britain could help the country save a “considerable amount of money” if it is used in future booster campaigns, according to the former chair of UK Vaccine Taskforce. Dr Clive Dix said that Nuvaxovid has excellent clinical data and – as a it has good stability at fridge temperatures – could be easily rolled out with the flu vaccine next winter, and should “replace the need to buy more Pfizer and Moderna vaccine.” Nu
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Intouch Solutions
FEBRUARY 3, 2022
Accolades Confirm Intouch as Among the Fastest-Rising Creative Agencies in the World. New York, NY — (Feb. 3, 2022) – Intouch Group, an EVERSANA company and a full-service global agency network serving the pharmaceutical industry, was ranked by Lürzer’s Archive as among the top five creative advertising agencies in the United States and top fifteen in the world.
Bio Pharma Dive
FEBRUARY 3, 2022
Executives for the pharma downplayed the impact of an accelerated approval for donanemab, pointing to Medicare's plans to restrict coverage of Alzheimer's drugs like it to only patients in clinical trials.
XTalks
JANUARY 31, 2022
Black Sheep Foods, a plant-based food tech company focused on heritage breed meats and wild game, recently raised $5.25 million in seed funding led by Bessemer Venture Partners. This investment brings the company’s total seed funding to $5.5 million since its launch in 2019. So, how does Black Sheep Foods make its uncommon meat analogues and will it face competition in a heavily saturated market ?
pharmaphorum
FEBRUARY 3, 2022
Novartis chief executive Vas Narasimhan has downplayed any chances of swift decision on the future of its generics business Sandoz, saying that a decision on the possible sale of the unit may not come until the last quarter of the year. The comments came despite rumours of another private equity bid for Sandoz, with Bloomberg saying it had got wind of a $25 billion combined bid from investment groups Blackstone and Carlyle, with others including Advent International, Hellman & Friedman and K
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Intouch Solutions
FEBRUARY 1, 2022
Digital health investments skyrocketed in 2021, increasing 79% from 2020, according to a year-end report by CB Insights , a marketing intelligence firm. This growing digital transformation within the healthcare industry was highlighted at CES 2022, with one of the main-stage keynote presentations by Robert Ford, President and CEO of Abbott. Ford discussed his vision and the promise of healthcare technology: to bring care that’s more personal and precise, proactively manage health, detect disease
Bio Pharma Dive
JANUARY 31, 2022
Pfizer concluded the data didn't support advancing the ANGPTL3-targeting drug — for which it paid $250 million two years ago to acquire the rights — despite positive study results.
Pharma Times
FEBRUARY 1, 2022
Market authorisation for twice yearly schizophrenia treatment which offers patients much-needed medication continuity
pharmaphorum
FEBRUARY 3, 2022
Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips for enjoying a big business career. This post looks at dealing with sudden stress and turning it into positive energy. We’ve all been there: stomach revolting, heart pounding, hands moist.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
323 
Let's personalize your content